Letter to the editor: Esophageal varices in Fontan patients - circulatory or hepatic failure?

  • Abstract
  • Similar Papers
Abstract
Translate article icon Translate Article Star icon
Take notes icon Take Notes

Letter to the editor: Esophageal varices in Fontan patients - circulatory or hepatic failure?

Similar Papers
  • Front Matter
  • 10.1016/j.xjon.2020.05.008
Commentary: Management of patients with failing Fontan: More questions than answers.
  • Jun 6, 2020
  • JTCVS open
  • Kirk R Kanter

Commentary: Management of patients with failing Fontan: More questions than answers.

  • Research Article
  • Cite Count Icon 9
  • 10.1016/j.cjca.2022.04.024
Cardiac Implantable Electronic Devices in the Fontan Patient.
  • Jul 1, 2022
  • Canadian Journal of Cardiology
  • Blandine Mondésert + 2 more

Cardiac Implantable Electronic Devices in the Fontan Patient.

  • Research Article
  • Cite Count Icon 2
  • 10.1016/j.ijcchd.2024.100521
Vitamin D deficiency and secondary hyperparathyroidism in adult Fontan patients
  • Jun 18, 2024
  • International Journal of Cardiology Congenital Heart Disease
  • Friederike Löffler + 7 more

Vitamin D deficiency and secondary hyperparathyroidism in adult Fontan patients

  • Research Article
  • Cite Count Icon 148
  • 10.1016/j.jhep.2020.04.024
Rebleeding and mortality risk are increased by ACLF but reduced by pre-emptive TIPS
  • Apr 24, 2020
  • Journal of Hepatology
  • Jonel Trebicka + 61 more

Rebleeding and mortality risk are increased by ACLF but reduced by pre-emptive TIPS

  • Front Matter
  • Cite Count Icon 7
  • 10.1016/j.xjtc.2021.12.019
Mechanical support for the failing single ventricle after Fontan
  • Feb 15, 2022
  • JTCVS Techniques
  • Chet Villa + 2 more

Mechanical support for the failing single ventricle after Fontan

  • Research Article
  • 10.1038/s41390-019-0346-3
Multisite measurement of regional oxygen saturation in Fontan patients with andwithout protein-losing enteropathy at rest and during exercise.
  • Feb 22, 2019
  • Pediatric Research
  • Simon Schröer + 10 more

Protein-losing enteropathy (PLE) is a severe complication of Fontan circulation with increased risk of end-organ dysfunction. We evaluated tissue oxygenation via near-infrared spectroscopy (NIRS) at different exercise levels in Fontan patients. Assessment of multisite NIRS during cycle ergometer exercise and daily activities in three groups: Fontan patients with PLE; without PLE; patients with dextro-transposition of the great arteries (d-TGA); comparing univentricular with biventricular circulation and Fontan with/without PLE. Renal threshold analysis (<65%;<55%;<45%) of regional oxygen saturation (rSO2) was performed. Fontan patients showed reduced rSO2 (p < 0.05) in their quadriceps femoris muscle compared with biventricular d-TGA patients at all time points. rSO2 in renal tissue was reduced at baseline (p = 0.002), exercise (p = 0.0062), and daily activities (p = 0.03) in Fontan patients with PLE. Renal threshold analysis identified critically low renal rSO2 (rSO2 < 65%) in Fontan patients with PLE during exercise (95% of monitoring time below threshold) and daily activities (83.7% time below threshold). Fontan circulation is associated with decreased rSO2 values in skeletal muscle and hypoxemia of renal tissue solely in patients with PLE. Reduced rSO2 already during activities of daily life, might contribute to comorbidities in patients with Fontan circulation, including PLE and renal failure.

  • Research Article
  • Cite Count Icon 16
  • 10.1007/s12072-022-10372-1
Acute variceal bleeding portends poor outcomes in patients with acute-on-chronic liver failure: a propensity score matched study from the APASL ACLF Research Consortium (AARC).
  • Jul 18, 2022
  • Hepatology International
  • Sanchit Sharma + 43 more

Limited data exist regarding outcomes of acute variceal bleeding (AVB) in patients with acute-on-chronic liver failure (ACLF), especially in those with hepatic failure. We evaluated the outcomes of AVB in patients with ACLF in a multinational cohort of APASL ACLF Research Consortium (AARC). Prospectively maintained data from AARC database on patients with ACLF who developed AVB (ACLF-AVB) was analysed. This data included demographic profile, severity of liver disease, and rebleeding and mortality in 6 weeks. These outcomes were compared with a propensity score matched (PSM) cohort of ACLF matched for severity of liver disease (MELD, AARC score) without AVB (ACLF without AVB). Of the 4434 ACLF patients, the outcomes in ACLF-AVB (n = 72) [mean age-46 ± 10.4years, 93% males, 66% with alcoholic liver disease, 65% with alcoholic hepatitis, AARC score: 10.1 ± 2.2, MELD score: 34 (IQR: 27-40)] were compared with a PSM cohort selected in a ratio of 1:2 (n = 143) [mean age-44.9 ± 12.5years, 82.5% males, 48% alcoholic liver disease, 55.7% alcoholic hepatitis, AARC score: 9.4 ± 1.5, MELD score: 32 (IQR: 24-40)] of ACLF-without AVB. Despite PSM, ACLF patients with AVB had a higher baseline HVPG than without AVB (25.00 [IQR: 23.00-28.00] vs. 17.00 [15.00-21.75] mmHg; p = 0.045). The 6-week mortality in ACLF patients with or without AVB was 70.8% and 53.8%, respectively (p = 0.025). The 6-week rebleeding rate was 23% in ACLF-AVB. Presence of ascites [hazard ratio (HR) 2.2 (95% CI 1.03-9.8), p = 0.026], AVB [HR 1.9 (95% CI 1.2-2.5, p = 0.03)], and MELD score [HR 1.7 (95% CI 1.1-2.1), p = 0.001] independently predicted mortality in the overall ACLF cohort. Development of AVB confers poor outcomes in patients with ACLF with a high 6-week mortality. Elevated HVPG at baseline represents a potential risk factor for future AVB in ACLF.

  • Discussion
  • Cite Count Icon 3
  • 10.1016/j.jhep.2020.05.001
Pre-emptive TIPS for acute variceal bleeding in acute-on-chronic liver failure: Is there enough evidence for a routine recommendation?
  • Jul 11, 2020
  • Journal of Hepatology
  • Anshuman Elhence + 2 more

Pre-emptive TIPS for acute variceal bleeding in acute-on-chronic liver failure: Is there enough evidence for a routine recommendation?

  • Research Article
  • Cite Count Icon 5
  • 10.1136/openhrt-2020-001460
Cross-sectional assessment of haemostatic profile and hepatic dysfunction in Fontan patients
  • May 1, 2021
  • Open Heart
  • Joelle Julius Nicolaas Daems + 10 more

BackgroundFontan-associated liver disease is accompanied by a hypercoagulable state. While hepatic dysfunction in Fontan patients is common, its relationship with haemostatic changes and clinical outcomes in this patient population remains...

  • Discussion
  • Cite Count Icon 6
  • 10.1002/hep.29680
Peptic ulcer bleeding in patients with cirrhosis: Is it as bad as variceal bleeding?
  • Feb 19, 2018
  • Hepatology
  • Gin‐Ho Lo + 1 more

Peptic ulcer bleeding (PUB) is among the most common causes of hospitalization worldwide, however, advances in endoscopic and pharmacological therapies have reduced the case fatality rate to 2.1% (1). In contrast, 6-week mortality of acute variceal bleeding (AVB) remained as high as 20% (2-3). Despite the considerable incidence of peptic ulcers with 6-33% and high recurrence rate of PUB in patients with cirrhosis (4), the specific mechanisms responsible for peptic ulcers remain largely unknown in the setting of cirrhosis (4). This article is protected by copyright. All rights reserved.

  • Research Article
  • Cite Count Icon 1
  • 10.1093/ejcts/ezae249
Liver fibrosis detected by diffusion-weighted magnetic resonance imaging and its functional correlates in Fontan patients.
  • Jun 24, 2024
  • European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
  • Chun-Wei Lu + 10 more

The evaluation of Fontan-associated liver disease is often challenging. Diffusion-weighted magnetic resonance imaging can detect hepatic fibrosis from capillary perfusion and diffusion abnormalities from extracellular matrix accumulation. This study investigated its role in the evaluation of liver disease in Fontan patients and explored possible diagnostic methods for early detection of advanced liver fibrosis. Stable adult Fontan patients who could safely be examined with magnetic resonance imaging were enrolled, and blood biomarkers, transient elastography were also examined. Forty-six patients received diffusion-weighted imaging; and 58.7% were diagnosed with advanced liver fibrosis (severe liver fibrosis, 37.0%, and cirrhosis 21.7%). Two parameters of hepatic dysfunction, platelet counts (Spearman's ρ: -0.456, P = 0.001) and cholesterol levels (Spearman's ρ: -0.383, P = 0.009), decreased with increasing severity of fibrosis. Using transient elastography, a cut-off value of 14.2 kPa predicted the presence of advanced liver fibrosis, but with a low positive predictive value. When we included platelet count, cholesterol, post-Fontan years and transient elastography values as a composite, the capability of predicting advanced liver fibrosis was the most satisfactory (C statistic 0.817 ± 0.071, P < 0.001). A cut-off value of 5.0 revealed a sensitivity of 78% and a specificity of 82%. In Fontan patients, diffusion-weighted imaging was helpful in detecting liver fibrosis that was correlated with hepatic dysfunction. A simple score was proposed for long-term surveillance and early detection of advanced liver disease in adult Fontan patients. For adult Fontan patients with a calculated score > 5.0, we may consider timely diffusion-weight imaging and early management for liver complications.

  • Research Article
  • Cite Count Icon 1
  • 10.1097/jcma.0000000000000185
Hepatic pathology in patients after Fontan operation: A computed tomography imaging study.
  • Nov 1, 2019
  • Journal of the Chinese Medical Association : JCMA
  • Yu-Chieh Chen + 9 more

Hepatic pathology in patients after Fontan operation: A computed tomography imaging study.

  • Research Article
  • Cite Count Icon 36
  • 10.1016/j.jjcc.2014.02.021
Iron deficiency and hematological changes in adult patients after Fontan operation
  • Mar 31, 2014
  • Journal of Cardiology
  • Lidia Tomkiewicz-Pajak + 8 more

Iron deficiency and hematological changes in adult patients after Fontan operation

  • Research Article
  • Cite Count Icon 81
  • 10.1016/s1542-3565(04)00465-3
Do antinuclear antibodies in primary biliary cirrhosis patients identify increased risk for liver failure?
  • Dec 1, 2004
  • Clinical Gastroenterology and Hepatology
  • Wei-Hong Yang + 5 more

Do antinuclear antibodies in primary biliary cirrhosis patients identify increased risk for liver failure?

  • Research Article
  • Cite Count Icon 44
  • 10.1097/00007890-199607270-00024
Fulminant hepatic failure from the Budd-Chiari syndrome. A bridge to transplantation with transjugular intrahepatic portosystemic shunt.
  • Jul 1, 1996
  • Transplantation
  • Paul C Kuo + 8 more

Fulminant hepatic failure from the Budd-Chiari syndrome. A bridge to transplantation with transjugular intrahepatic portosystemic shunt.

More from: Hepatology (Baltimore, Md.)
  • New
  • Research Article
  • 10.1097/hep.0000000000001502
Introducing Saul J. Karpen, MD, PhD, the 77th President of AASLD.
  • Nov 7, 2025
  • Hepatology (Baltimore, Md.)
  • Paul A Dawson + 3 more

  • New
  • Research Article
  • 10.1097/hep.0000000000001608
Semaglutide therapy for metabolic dysfunction-associated steatohepatitis: November 2025 updates to AASLD Practice Guidance.
  • Nov 7, 2025
  • Hepatology (Baltimore, Md.)
  • Meena B Bansal + 5 more

  • New
  • Research Article
  • 10.1097/hep.0000000000001605
GPC3-based circular RNA vaccine suppresses hepatocellular carcinoma progression by activating adaptive immune responses.
  • Nov 7, 2025
  • Hepatology (Baltimore, Md.)
  • Yifan Jiang + 11 more

  • New
  • Research Article
  • 10.1097/hep.0000000000001589
2025 Late Breaking Abstracts.
  • Nov 7, 2025
  • Hepatology (Baltimore, Md.)

  • New
  • Research Article
  • 10.1097/hep.0000000000001606
KLF9 drives intermittent hypoxia-induced NAFLD by suppressing the NR4A1-p38 MAPK hepatic metabolic axis.
  • Nov 4, 2025
  • Hepatology (Baltimore, Md.)
  • Hongting Hua + 15 more

  • New
  • Research Article
  • 10.1097/hep.0000000000001549
AASLD/IDSA Practice Guideline on treatment of chronic hepatitis B.
  • Nov 4, 2025
  • Hepatology (Baltimore, Md.)
  • Marc G Ghany + 15 more

  • New
  • Research Article
  • 10.1097/hep.0000000000001582
Commentary - AASLD Practice Guideline on treatment of chronic hepatitis B (2025 Update).
  • Nov 4, 2025
  • Hepatology (Baltimore, Md.)
  • Alexander J Thompson + 1 more

  • New
  • Research Article
  • 10.1097/hep.0000000000001590
Epigenetic repression of hepatocyte FoxO1 disrupts local immune homeostasis and promotes liver inflammation.
  • Nov 4, 2025
  • Hepatology (Baltimore, Md.)
  • Zhigang Lei + 17 more

  • New
  • Research Article
  • 10.1097/hep.0000000000001584
Technical systematic review supporting 2025 AASLD Practice Guidelines on management of chronic hepatitis B.
  • Nov 4, 2025
  • Hepatology (Baltimore, Md.)
  • Calvin Q Pan + 21 more

  • New
  • Research Article
  • 10.1097/hep.0000000000001604
Beyond AUROC: Critical evaluation of FSTL-1 as a liver fibrosis biomarker.
  • Nov 3, 2025
  • Hepatology (Baltimore, Md.)
  • Yoshiyasu Takefuji

Save Icon
Up Arrow
Open/Close
  • Ask R Discovery Star icon
  • Chat PDF Star icon

AI summaries and top papers from 250M+ research sources.

Search IconWhat is the difference between bacteria and viruses?
Open In New Tab Icon
Search IconWhat is the function of the immune system?
Open In New Tab Icon
Search IconCan diabetes be passed down from one generation to the next?
Open In New Tab Icon